3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
39
Neoplasm Metastasis
5
Prostatic Neoplasms, Castration-Resistant
2
Castration-resistant Prostate Cancer
2
Thrombocytosis
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oligometastatic Prostate Carcinoma
1
Oligo-metastatic Prostate Carcinoma
1
Neoadjuvant Therapy
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
enzalutamide
4
abiraterone
2
Radiotherapy
2
Metastasectomy
2
Abiraterone Acetate
2
testosterone enanthate
1
pembrolizumab
1
Radium-223
1
Radiosurgery
1
Prednisone
1
Ketoconazole
1
Injections
1
Hydrocortisone
1
Flutamide
1
Crizotinib
1
Control Groups
1
Carboplatin
1
Calcitriol
1
Blood Specimen Collection
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Castration-resistant Prostate Cancer
×
abiraterone
×
Clear all
NCT04839055
2021-04-09
CoA-CRPC
Jiangnan University
Phase 1/2
Unknown
50 enrolled
NCT02429193
2020-01-13
BARRIER-P
University Health Network, Toronto
Phase 2
Completed
16 enrolled